Armadin solution for injection 50 mg/ml, 2ml x 10 ampoules — Made in Ukraine — Free Delivery

Pharmacological properties

Pharmacological.

ARMADIN is an inhibitor of free radical processes, membrane protector, has antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The preparation increases the body's resistance to the effects of various damaging factors, to acidic pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, alcohol and antipsychotic preparations (neuroleptics) intoxication).

The preparation improves cerebral metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins (LDL). Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

The mechanism of action of the preparation is due to its antioxidant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Modulates the activity of membrane-binding enzymes (calcium-non-depleted phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, γ-aminobutyric acid (GABA), acetylcholine), which enhances their ability to bind to ligandamines' functional organization, transmission. ARMADINE increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in the content of adenosine triphosphate (ATP) and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

ARMADIN normalizes metabolic processes in the ischemic myocardium, reduces the zone of necrosis, restores and improves the electrical activity and contractility of the myocardium, and also increases coronary blood flow in the ischemic zone, and reduces the consequences of reperfusion syndrome in acute coronary insufficiency. Increases the antianginal activity of nitro preparations. ARMADIN contributes to the preservation of retinal ganglion cells and optic nerve fibers in progressive neuropathy, the consequences of which are chronic ischemia and hypoxia. Improves the functional activity of the retina and optic nerve, increasing visual acuity.

Pharmacokinetics.

When administered, the preparation is determined in blood plasma within 4:00 after administration. The time to reach the maximum concentration is 0.45-0.5 hours. The maximum concentration at doses of 400-500 mg is 3.5-4.0 μg / ml. ARMADIN quickly passes from the bloodstream to the organs of the i tissue and is quickly excreted from the body. It is excreted from the body in the urine, mainly in glucuronoconjugation form and in small quantities - unchanged.

Indications

• Acute disorders of cerebral circulation

• traumatic brain injury, the consequences of traumatic brain injury;

• encephalopathy

• cardiopsychoneurosis;

• mild cognitive impairment of atherosclerotic genesis;

• anxiety disorders in neurotic i neurosis-like states;

• acute myocardial infarction (from the first day), as part of complex therapy

• primary open-angle glaucoma of various stages, as part of complex therapy

• relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

• acute intoxication with antipsychotic preparations;

• acute purulent-inflammatory processes in the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Contraindications

Hypersensitivity to the preparation, acute hepatic or renal failure. During pregnancy and breastfeeding. Childhood.

Interaction with other medicinal products and other forms of interaction

ARMADIN enhances the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian preparations (levodopa). Reduces the toxic effect of ethyl alcohol.

Increases the antianginal activity of nitro preparations and the antihypertensive action of ACE and β-blockers. Combined use with nibentan, propranolol and verapamil reduces the risk of developing arrhythmogenic effects of the latter, combined use with antipsychotics reduces the risk of developing and the severity of side effects of the latter.

Application features

In some cases, especially in predisposed patients, in patients with bronchial asthma, with hypersensitivity to sulfites, severe hypersensitivity reactions may develop. It should be used with limitations in patients with diabetic retinopathy (the course should not exceed 7-10 days) due to the property of enhancing proliferative processes.

After the completion of parenteral administration, in order to maintain the achieved effect, it is recommended to continue using the preparation inside in the form of tablets.

Use during pregnancy or lactation

Strictly controlled clinical studies of the safety of the preparation during pregnancy and lactation have not been carried out, therefore, ARMADIN should not be used during these periods.

The ability to influence the reaction rate when driving or driving other mechanisms

During the period of treatment, care must be taken when driving vehicles or working with mechanisms, given the likelihood of side effects that may affect the reaction rate and the ability to concentrate.

Method of administration and dosage

Administer ARMADIN intramuscularly or intravenously (jet or drip). Doses are selected individually. When administered by infusion, the preparation should be diluted in 0.9% sodium chloride solution (200 ml). Start treatment for adults with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose until a therapeutic effect is obtained. Inject ARMADIN in a jet slowly for 5-7 minutes, drip - at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 800 mg.

In acute disorders of cerebral circulation, ARMADIN should be prescribed in complex therapy in the first 2-4 days by intravenous drip for adults at 200-300 mg 1 time per day, then intramuscularly at 100 mg 3 times a day. The treatment period is 10-14 days.

In case of traumatic brain injury and the consequences of traumatic brain injury, ARMADIN should be used for 10-15 days by intravenous drip of 200-500 mg 2-4 times a day.

In case of discirculatory encephalopathy in the decompensation phase, ARMADIN should be administered by drip in a dose of 100 mg 2-3 times a day for 14 days. Then the preparation is administered intramuscularly at 100 mg per day for 2 weeks.

For the course prevention of discirculatory encephalopathy, the preparation should be administered to adults intramuscularly at 100 mg 2 times a day for 10-14 days.

In case of mild cognitive impairment in elderly patients and in anxiety conditions, the preparation should be administered intramuscularly at a dose of 100-300 mg per day for 14-30 days.

In acute myocardial infarction, as part of a complex therapy, ARMADIN should be administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, β-blockers, ACE inhibitors (ACE), thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic agents for indications. In the first 5 days, to achieve the maximum effect, it is desirable to administer the preparation ARMADIN, in the next 9 days, intramuscular administration is possible. The introduction of the preparation ARMADIN is carried out by drop infusion, slowly (to avoid side effects), on 0.9% sodium chloride solution or 5% glucose solution in a volume of 100-150 ml for 30-90 minutes. If necessary, a slow jet injection of the preparation is possible for at least 5 minutes.

The introduction of the preparation ARMADIN (intravenously or intramuscularly) is carried out 3 times a day, every 8:00. The daily therapeutic dose is 6-9 mg per kilogram of body weight per day, a single dose is 2-3 mg / kg of body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.

In case of open-angle glaucoma of different stages, as part of the complex therapy, ARMADIN is administered intramuscularly at 100-300 mg per day, 1-3 times a day for 14 days.

In case of alcohol withdrawal syndrome, ARMADIN should be administered at a dose of 100-200 mg 2-3 times a day or intravenously 1-2 times a day for 5-7 days.

In case of acute intoxication with antipsychotic preparations, the preparation should be administered at a dose of 50-300 mg per day for 7-14 days.

In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis), the preparation should be prescribed on the first day both in the preoperative period and in the postoperative period. Doses depend on the form and severity of the disease, the prevalence of the process, and the options for the clinical course. The preparation should be withdrawn gradually, only after a stable positive clinical and laboratory effect.

In acute edematous (interstitial) pancreatitis, ARMADIN should be prescribed 100 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly. Mild severity of necrotizing pancreatitis: 100-200 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly. Moderate severity: adults - 200 mg 3 times a day intravenously drip (in 0.9% sodium chloride solution). Severe course: at a pulse dosage of 800 mg per day with a double dose, then - 300 mg 2 times a day with a gradual decrease in the daily dose. Very severe course: at an initial dose of 800 mg per day until stable relief of the manifestation of pancreatogenic shock, after stabilization of the state - 300-400 mg twice a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dose.

Children

There have not been strictly controlled clinical studies of the safety of the preparation in children; therefore, ARMADIN should not be used in this category of patients.

Overdose

In case of an overdose, drowsiness, insomnia are possible, with intravenous administration, in some cases, a short-term and slight increase in blood pressure is possible.

The development of symptoms of an overdose, as a rule, does not require the use of cupping agents. These symptoms of sleep disorders disappear on their own within a day. In especially severe cases, it is recommended to use one of the tableted hypnotics and anxiolytics (nitrazepam 10 mg, oxazepam 10 mg, diazepam 5 mg). With an excessive increase in blood pressure, antihypertensive preparations should be used under the control of blood pressure and / or supplemented with nitrate-lowering preparations. Treatment is detoxification therapy.

Side effects

On the part of the cardiovascular system: increase or decrease in blood pressure.

From the nervous system: dizziness, drowsiness, impaired sleep, anxiety, emotional reactivity, headache, lack of coordination.

From the digestive system: nausea, dryness of the oral mucosa.

From the side of the immune system: with individual hypersensitivity to the preparation, allergic reactions may occur, including rash, urticaria, itching, angioedema, severe hypersensitivity reactions, bronchospasm are possible.

On the part of the skin and subcutaneous tissue: distal hyperhidrosis, changes at the injection site.

With intravenous administration, especially jet, there may be a metallic taste in the mouth, a feeling of heat throughout the body, an unpleasant odor, sore throat and discomfort in the chest, shortness of breath, palpitations, tachycardia, tremor, facial flushing. As a rule, these phenomena are associated with an excessive rate of preparation administration and have a short-term character.

Against the background of prolonged administration of the preparation, such side effects may occur: flatulence, weakness, peripheral edema.

Shelf life

5 years.

Storage conditions

Store at a temperature not exceeding 30 ° C in its original packaging.

Keep out of the reach of children.